COVID-19 Vaccine Race Will Need To Eliminate Development ‘Dead Space’
Executive Summary
As Pfizer begins human trials, CBER’s Marks eyes nine-month target for a vaccine and urges at-risk manufacturing once a candidate reaches Phase III.
You may also be interested in...
Moderna’s Early Data On COVID-19 Vaccine Prompts Dosing Revisions For Phase II
Move to lower doses could ease manufacturing scale-up burden a bit; first eight volunteers produced antibodies which match or surpass those seen in patients who have recovered from COVID-19 – but big test awaits in Phase III.
Can GSK Veteran Moncef Slaoui Get COVID-19 Vaccine Development To Warp Speed?
President Trump's Operation Warp Speed initiative aims to have a COVID-19 vaccine available by the end of the year; Slaoui, who helped get the first cervical cancer vaccine to market and win European approval of the first malaria vaccine while at GlaxoSmithKline, is tasked with coordinating the government's contributions to coronavirus vaccine effort and achieving what would be twin scientific and manufacturing miracles.
An Ambitious COVID-19 Vaccine Development Plan For Pfizer And BioNtech
Pfizer said it is dosing patients now with an mRNA-based vaccine and expects human data in May/June, with a goal to have a vaccine available for emergency use possibly by October.